In the Claims:

1. (currently amended) ~~Orally~~ An orally administrable film-shaped medicament containing at least one of the active substance deoxypeganine ~~or/and~~ and a deoxypeganine derivative.

2. (currently amended) ~~Medicament~~ The medicament according to claim 1, ~~characterized in that it~~ wherein said medicament contains at least one of a pharmaceutically acceptable salt of deoxypeganine ~~or/and~~ and a pharmaceutically acceptable salt of a derivative of deoxypeganine~~, with deoxypeganine hydrochloride and deoxypeganine hydrobromide being preferred as salts~~.

3. (currently amended) ~~Medicament~~ The medicament according to claim ~~claims~~ 1, wherein said medicament ~~or 2, characterized in that it~~ is suitable for transmucosal~~, especially buccal,~~ administration of said at least one [[the]] active substance ~~substance(s) contained therein~~.

4. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ has at least one polymer-containing layer which serves as an active substance reservoir and contains [[the]] said at least one active ~~substance(s)~~ substance, and wherein said ~~with the~~ polymer portion is present in an amount between ~~amounting to~~ 10 to 90%-wt~~, preferably 20 to 70% wt, particularly preferably 20 to 60% wt~~.

5. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ has a two-, three- or multilayer structure, [[with]] wherein at least one layer contains ~~containing~~ an active substance selected from the group ~~comprising~~ consisting of deoxypeganine, deoxypeganine derivatives and salts of ~~the said substances~~ deoxypeganine and deoxypeganine derivatives.

6. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein ~~any one of the preceding claims, characterized in that~~ the content of said at least one active substance ~~content~~ is 0.5 to 40%-wt~~, preferably 5 to 30% wt~~.

7. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein the ~~any one of the preceding claims, characterized in that its~~ overall thickness of said medicament is 0.05 to 3 mm~~, preferably 0.1 to 1 mm, especially preferably 0.1 to 0.5 mm~~.

8. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ is mucoadhesive or has at least one mucoadhesive outer surface.

9. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ is soluble in an aqueous media~~, especially in saliva~~, and wherein ~~it being preferred that~~ the dissolution takes place ~~within~~ between 1 second [[s up to]] and 5 minutes ~~min, especially preferably within 3 to 30 s~~.

10. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament is ~~any one of the preceding claims, characterized in that it~~ quickly ~~disintegrates~~ disintegratable in an aqueous media~~, especially in saliva~~, and wherein the disintegration takes place ~~preferably~~ within 1 [[s]] second to 5 minutes ~~min, especially preferably within 3 to 30 s~~.

11. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ is ~~capable of gelatinizing~~ gelatinizable or ~~swelling~~ swellable in an aqueous media~~, especially in saliva~~.

12. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ has a depot effect or releases [[the]] said at least one active substance ~~substance(s)~~ with a delay in time~~, preferably~~ over a period of time of up to 8 hours ~~h, especially up to 24 h~~.

13. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ has at least one rapidly releasing active substance-containing layer and at least one layer with retarded active substance release.

14. (currently amended) ~~Medicament~~ The medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in that it~~ additionally contains at least one further pharmaceutically active substance which is not selected from the group ~~including~~ consisting of deoxypeganine, deoxypeganine derivatives and salts of deoxypeganine and deoxypeganine derivatives ~~the said substances~~.

15. (currently amended) ~~Film-shaped~~ The film-shaped medicament according to claim 1, wherein said medicament ~~any one of the preceding claims, characterized in~~

~~that it~~ contains at least one ~~or more~~ auxiliary ~~substances~~ substance.

16. (currently amended) [[Use]] A use of at least one cholinergic active substance acting on the central nervous system selected from the at least one active substance recited ~~substances mentioned~~ in claim ~~claims~~ 1 [[and 2]] for ~~the production of~~ producing an oral, film-shaped medicament for administering [[the]] said at least one active substance ~~substance(s)~~ for ~~the treatment of~~ treating diseases or symptoms caused by acetylcholine deficiency or where such a deficiency occurs, as well as for ~~the treatment of~~ treating at least one of diseases where a deficiency of endogenous amine occurs ~~and/or~~ and diseases which can be favourably influenced by inhibition of monoaminoxidase, said use comprising the step of introducing said medicament into the oral cavity at intervals between 1 and 6 hours and wherein the daily dose of said at least one active substance is between 50 and 750 mg.

17. (currently amended) [[Use]] The use according to claim 16, ~~characterized in that~~ ~~the~~ wherein said film-shaped medicament is a medicament according to ~~one of the claims~~ claim 1 [[to 15]].

18. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17, characterized in that~~ the medicament is used for ~~the treatment of~~ treating Alzheimer's disease or [[of]] symptoms caused by Alzheimer's disease.

19. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17, characterized in that~~ the medicament is used for ~~the treatment of~~ treating a condition selected from the group of conditions consisting of depressions, schizophrenia [[or]] and manic disorders.

20. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17, characterized in that~~ the medicament is used for treating chronic fatigue syndrome or disturbed sleep.

21. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17, characterized in that~~ the medicament is used for treating abuse of alcohol or for treating abuse of nicotine.

22. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17, characterized in that~~ the medicament is used for the therapy of abuse of chemical substances, ~~especially~~ psychotropic substances, or the dependence on such substances.

23. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17,~~

~~characterized in that~~ the medicament is used for the prophylactic treatment of poisonings caused by organophosphorous cholinesterase inhibitors.

24. (currently amended) [[Use]] The use according to claim 16, wherein ~~or 17, characterized in that~~ the medicament is used for ~~the treatment of~~ treating disorders of the central nervous system~~, particularly impaired memory~~, which have been caused by the action of psychotropic substances.

25. (new) The medicament according to claim 2, wherein said pharmaceutically acceptable salt of a derivative of deoxypeganine is selected from the group consisting of deoxypeganine hydrochloride and deoxypeganine hydrobromide.

26. (new) The medicament according to claim 3, wherein said medicament is suitable for buccal, administration of said at least one active substance.

27. (new) The medicament according to claim 4, wherein said polymer portion is present in an amount between 20 to 70%-wt.

28. (new) The medicament according to claim 27, wherein said polymer portion is present in an amount between 20 to 60%-wt.

29. (new) The medicament according to claim 6, wherein the content of said at least one active substance is 5 to 30%-wt.

30. (new) The medicament according to claim 7, wherein the overall thickness of said medicament is 0.1 to 1 mm.

31. (new) The medicament according to claim 30, wherein the overall thickness of said medicament is 0.1 to 0.5 mm.

32. (new) The medicament according to claim 9, wherein said aqueous media is saliva.

33. (new) The medicament according to claim 9, wherein said dissolution takes place between 3 and 30 seconds.

34. (new) The medicament according to claim 10, wherein said aqueous media is saliva.

35. (new) The medicament according to claim 10, wherein said disintegration takes place within 3 to 30 seconds.

36. (new) The medicament according to claim 11, wherein said aqueous media is saliva.

37. (new) The medicament according to claim 12, wherein said delay in time is a period up to 24 hours.

38. (new) The use according to claim 24, wherein the medicament is used for treating disorders of impaired memory.